受体三阴性乳腺癌的分子特征与治疗研究进展

Advances of molecular characteristics and treatment in triple negative breast cancers

乳腺癌现有的临床病理参数(如淋巴结状态、肿瘤大小、病理分级、类固醇激素受体、HER-2等)对于判断预后和指导临床治疗有非常重要的作用,DNA微阵列技术和多基因RT-PCR定量检测等分子生物学技术对乳腺癌进行分子分型、研究新亚型乳腺癌的生物学特性和预后,对于指导临床治疗与随访有更高价值。如受体三阴性乳腺癌(TNBC)与luminal A、luminal B、HER-2^+和normal-like亚群相比复发早、进展快、生存短,成为临床普遍关注的重点之一,这些ER/PR/HER-2三阴性乳腺癌患者的预后和治疗有诸多困难,至今没有针对性的治疗,本文综述了相关的分子病理、体外研究、临床探索性治疗和新药研究等进展。

The clinical pathological characteristics （lymph node status, tumor size, pathological grade, hormone receptor, and HER -2 status） are important parameters to predict the prognosis and guide treatment in breast cancer. In recent years, some molecular subtypes have been determined by DNA microarrays and RT - PCR, including the ＂triple negative＂ breast cancers （ ER negative, PR negative, and HER - 2 negative）. The triple negative breast cancers have faster progression, earlier relapse, and shorter survive when compared with other subtypes （luminal A, luminal B, HER -2 positive, and Nomal -like）. These cancers are still poorly understood and treated.